Dexcom (DXCM) Cash & Equivalents (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash & Equivalents data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Cash & Equivalents rose 23.57% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 23.57% YoY) and the FY2025 annual result came in at $392.8 million, up 192.7% from the prior year.
• Cash & Equivalents climbed to $1.1 billion in Q1 2026 per DXCM's latest filing, from $392.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.4 billion in Q3 2025 and bottomed at $134.2 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $698.1 million (2022), against an average of $750.9 million.
• The widest annual swing landed in 2024, when Cash & Equivalents plunged 76.3%; it then surged 192.7% in 2025.
• Tracing DXCM's Cash & Equivalents over 5 years: stood at $642.3 million in 2022, then retreated by 11.83% to $566.3 million in 2023, then sank by 76.3% to $134.2 million in 2024, then surged by 192.7% to $392.8 million in 2025, then surged by 184.67% to $1.1 billion in 2026.
• Per Business Quant, the three latest DXCM Cash & Equivalents figures stand at $1.1 billion (Q1 2026), $392.8 million (Q4 2025), and $1.4 billion (Q3 2025).

Peer Comparison